On Topic Virtual Roundtable: “BTK Battle” – Experts Compare and Contrast the Latest Data of BTK Inhibitors for the Treatment of Hematologic Malignancies
Released On
January 31, 2023
Expires On
January 31, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Education, Hematology-Oncology
Topic(s)
Leukemia, Oncology
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Bio Ascend.
This activity is supported by an independent educational grant from AstraZeneca.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Downloadable Slides
Program Overview
This online roundtable discussion will focus on the use of BTK in patients with CLL/SLL, lymphoma, and other hematologic malignancies, as well as expert guidance in the selection and sequencing of this class of agents safely and effectively.
Target Audience
The target audience for this activity is community and academic medical oncologists, pulmonologists, allied health professionals, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Evaluate the safety and efficacy of currently approved BTK inhibitors for patients with hematologic malignancies, including CLL/SLL, lymphoma, and Waldenström’s macroglobulinemia
- Review clinical trial results of emerging BTK-inhibitor-based strategies that are being investigated in patients with hematologic malignancies
- Compare and contrast the safety and efficacy of BTK inhibitors in order to properly select and sequence this class of agents in patients with newly diagnosed and relapsed/refractory hematologic malignancies
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Topics of Discussion
Module 1: Ibrutinib for Hematologic Malignancies
Module 2: Acalabrutinib for Hematologic Malignancies
Module 3: Zanubrutinib for Hematologic Malignancies
Module 4: Emerging BTK Inhibitors
Module 5: Experts Debate Optimal Selection and Sequencing Strategies
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Matthew Davids, MD, MMSc (Moderator)
Director, Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.
Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.
Catherine Coombs, MD
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Grants/Research Support: LOXO/Lilly and AbbVie, Paid to institution
Speakers Bureau/Honoraria for non-CME: Genentech, AbbVie, AstraZeneca, Beigene, LOXO/Lilly
Consultant/Advisory Board: Genentech, AbbVie, AstraZeneca, Beigene, LOXO/Lilly, TG Therapeutics, MEI Pharma, Octapharma, Janssen
Non-Mutual funds Stock Ownership/Stock options: CTI Biopharma, Bluebird Bio
Anthony Mato, MD, MSCE
Medical Oncologist/CLL Specialist
New York, New York
Grants/Research Support: AbbVie, Genentech, LOXO, DTRM, Genmab, AZ, Beigene, Nurix, Pharmacyclics
Consultant/Advisory Board: Abbvie, Genentech, LOXO, DTRM, Genmab, AZ, Beigene, Nurix, Pharmacyclics
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Contact Information
For CME questions please contact: info@bioascend.com